The pharmacogenetic testing market size has grown rapidly in recent years. It will grow from $14.33 billion in 2025 to $16.58 billion in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to advances in genomic sequencing technologies, adverse drug reaction concerns, rising chronic disease burden, declining genetic testing costs, increased clinical awareness.
The pharmacogenetic testing market size is expected to see rapid growth in the next few years. It will grow to $29.55 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to growth of precision healthcare, expansion of direct-to-consumer testing, integration with electronic health records, increasing regulatory support, rising investment in genomics research. Major trends in the forecast period include rising adoption of personalized medicine, increasing use of genetic testing in drug selection, expansion of oncology and cardiology applications, growing demand for precision diagnostics, integration of pharmacogenomics in clinical practice.
The rising demand for personalized medicine is anticipated to fuel the expansion of the pharmacogenetic testing market in the future. Personalized medicine, also known as precision medicine, involves a medical strategy that customizes treatments and decisions based on a person's distinct genetic, biological, and lifestyle factors. This demand is growing because it enhances treatment effectiveness, enables earlier detection, and boosts cost-efficiency in healthcare. Pharmacogenetic testing aids personalized medicine by examining a patient's genetic makeup to forecast drug responses, allowing for better treatment choices and minimizing adverse effects. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based non-profit, reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from 6 in 2022. Thus, the growing need for personalized medicine is propelling the pharmacogenetic testing market forward.
Major companies in the pharmacogenetics testing market are prioritizing the development of sophisticated pharmacogenomics testing services, including prescription-based pharmacogenetic testing, to boost medication safety, enhance treatment accuracy, and facilitate personalized therapeutic choices. Prescription-based pharmacogenetic testing involves genetic testing prescribed by qualified healthcare providers to assess how a person's genetic profile affects their response to particular drugs, enabling doctors to refine drug selection and dosage to lower the risk of adverse reactions. For example, in May 2023, UCSF, a US-based healthcare provider, introduced its pharmacogenomics testing service to increase the precision of medical treatments, offering clinicians genetic data that allows them to customize drug therapies to individual patient profiles, boost drug effectiveness, and reduce the chance of serious side effects.
In May 2023, HealthŌme - a US-based company focused on advanced genetic testing and personalized medicine - acquired Kailos Genetics for an undisclosed sum. The deal bolsters HealthŌme’s personalized medicine offerings by incorporating Kailos Genetics’ cutting-edge genomic technologies and pharmacogenetic expertise. It also amplifies HealthŌme’s capacity to provide full-spectrum precision-testing services via deeper knowledge in genomic analysis and tailored treatment recommendations. Kailos Genetics, a US-based firm, delivers pharmacogenetic testing via its Inspexion platform.
Major companies operating in the pharmacogenetic testing market are CVS Health Corporation, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Eurofins Scientific Inc., Bio-Rad Laboratories, Precision Medicine Advsiors, Azenta Life Sciences, Fulgent Genetics, Pacific Biosciences of California Inc., Castle Biosciences, 23andMe Holding Co., Helix Inc., Genomind Inc., MD Labs, Sonic Genetics, AutoGenomics Inc., LabClinics SA, Gene By Gene Ltd., Xcode Life Sciences, YouScript, RxGenomix LLC.
Asia-Pacific was the largest region in the pharmacogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmacogenetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the pharmacogenetic testing market by raising the cost of imported sequencing instruments, reagents, and assay components used in genetic analysis. These effects are most pronounced in Asia Pacific and emerging markets that rely heavily on imported diagnostic technologies. Rising tariff related costs have increased testing expenses and influenced laboratory investment decisions. This has affected the pace of pharmacogenetic test adoption in clinical and research settings. However, tariffs are also supporting the development of domestic diagnostic manufacturing, local assay production, and stronger regional testing ecosystems over time.
The pharmacogenetic testing market research report is one of a series of new reports that provides pharmacogenetic testing market statistics, including pharmacogenetic testing industry global market size, regional shares, competitors with a pharmacogenetic testing market share, detailed pharmacogenetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacogenetic testing industry. This pharmacogenetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Pharmacogenetic testing involves genetic analysis that reveals how a person's genes affect their response to particular drugs, enabling customized medication strategies for improved effectiveness and fewer adverse effects. This individualized method improves patient outcomes by aligning treatments with genetic characteristics. It finds broad application in areas like oncology, psychiatry, and cardiology.
The primary types of pharmacogenetic testing include whole genome sequencing, whole exome sequencing, array-based tests, and single gene tests. Whole genome sequencing offers a thorough approach to examining an organism's full genome. It sequences all DNA in one test, delivering a detailed view of a person's genetic profile. Drug types encompass prescription medications, nutraceuticals, recreational drugs, herbal supplements, vitamins, and over-the-counter drugs across various therapeutic fields like cardiology, gastroenterology, anesthesiology, genomics, endocrinology, immunology and hypersensitivity, dermatology, gynecology, oncology, and more. These are available via hospital pharmacies, retail pharmacies, mail-order pharmacies, and direct-to-consumer channels, serving end users such as healthcare providers, pharmaceutical and biotechnology firms, research centers, academic institutions, and others.
The pharmacogenetic testing market consists of revenues earned by entities by providing services such as predicting drug efficacy, guiding dosage selection, and preventing adverse drug reactions. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmacogenetic testing market also includes sales of gene panels, deoxyribonucleic acid (DNA) sequencers, and home testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The pharmacogenetic testing market size is expected to see rapid growth in the next few years. It will grow to $29.55 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to growth of precision healthcare, expansion of direct-to-consumer testing, integration with electronic health records, increasing regulatory support, rising investment in genomics research. Major trends in the forecast period include rising adoption of personalized medicine, increasing use of genetic testing in drug selection, expansion of oncology and cardiology applications, growing demand for precision diagnostics, integration of pharmacogenomics in clinical practice.
The rising demand for personalized medicine is anticipated to fuel the expansion of the pharmacogenetic testing market in the future. Personalized medicine, also known as precision medicine, involves a medical strategy that customizes treatments and decisions based on a person's distinct genetic, biological, and lifestyle factors. This demand is growing because it enhances treatment effectiveness, enables earlier detection, and boosts cost-efficiency in healthcare. Pharmacogenetic testing aids personalized medicine by examining a patient's genetic makeup to forecast drug responses, allowing for better treatment choices and minimizing adverse effects. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based non-profit, reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from 6 in 2022. Thus, the growing need for personalized medicine is propelling the pharmacogenetic testing market forward.
Major companies in the pharmacogenetics testing market are prioritizing the development of sophisticated pharmacogenomics testing services, including prescription-based pharmacogenetic testing, to boost medication safety, enhance treatment accuracy, and facilitate personalized therapeutic choices. Prescription-based pharmacogenetic testing involves genetic testing prescribed by qualified healthcare providers to assess how a person's genetic profile affects their response to particular drugs, enabling doctors to refine drug selection and dosage to lower the risk of adverse reactions. For example, in May 2023, UCSF, a US-based healthcare provider, introduced its pharmacogenomics testing service to increase the precision of medical treatments, offering clinicians genetic data that allows them to customize drug therapies to individual patient profiles, boost drug effectiveness, and reduce the chance of serious side effects.
In May 2023, HealthŌme - a US-based company focused on advanced genetic testing and personalized medicine - acquired Kailos Genetics for an undisclosed sum. The deal bolsters HealthŌme’s personalized medicine offerings by incorporating Kailos Genetics’ cutting-edge genomic technologies and pharmacogenetic expertise. It also amplifies HealthŌme’s capacity to provide full-spectrum precision-testing services via deeper knowledge in genomic analysis and tailored treatment recommendations. Kailos Genetics, a US-based firm, delivers pharmacogenetic testing via its Inspexion platform.
Major companies operating in the pharmacogenetic testing market are CVS Health Corporation, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Eurofins Scientific Inc., Bio-Rad Laboratories, Precision Medicine Advsiors, Azenta Life Sciences, Fulgent Genetics, Pacific Biosciences of California Inc., Castle Biosciences, 23andMe Holding Co., Helix Inc., Genomind Inc., MD Labs, Sonic Genetics, AutoGenomics Inc., LabClinics SA, Gene By Gene Ltd., Xcode Life Sciences, YouScript, RxGenomix LLC.
Asia-Pacific was the largest region in the pharmacogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmacogenetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the pharmacogenetic testing market by raising the cost of imported sequencing instruments, reagents, and assay components used in genetic analysis. These effects are most pronounced in Asia Pacific and emerging markets that rely heavily on imported diagnostic technologies. Rising tariff related costs have increased testing expenses and influenced laboratory investment decisions. This has affected the pace of pharmacogenetic test adoption in clinical and research settings. However, tariffs are also supporting the development of domestic diagnostic manufacturing, local assay production, and stronger regional testing ecosystems over time.
The pharmacogenetic testing market research report is one of a series of new reports that provides pharmacogenetic testing market statistics, including pharmacogenetic testing industry global market size, regional shares, competitors with a pharmacogenetic testing market share, detailed pharmacogenetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacogenetic testing industry. This pharmacogenetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Pharmacogenetic testing involves genetic analysis that reveals how a person's genes affect their response to particular drugs, enabling customized medication strategies for improved effectiveness and fewer adverse effects. This individualized method improves patient outcomes by aligning treatments with genetic characteristics. It finds broad application in areas like oncology, psychiatry, and cardiology.
The primary types of pharmacogenetic testing include whole genome sequencing, whole exome sequencing, array-based tests, and single gene tests. Whole genome sequencing offers a thorough approach to examining an organism's full genome. It sequences all DNA in one test, delivering a detailed view of a person's genetic profile. Drug types encompass prescription medications, nutraceuticals, recreational drugs, herbal supplements, vitamins, and over-the-counter drugs across various therapeutic fields like cardiology, gastroenterology, anesthesiology, genomics, endocrinology, immunology and hypersensitivity, dermatology, gynecology, oncology, and more. These are available via hospital pharmacies, retail pharmacies, mail-order pharmacies, and direct-to-consumer channels, serving end users such as healthcare providers, pharmaceutical and biotechnology firms, research centers, academic institutions, and others.
The pharmacogenetic testing market consists of revenues earned by entities by providing services such as predicting drug efficacy, guiding dosage selection, and preventing adverse drug reactions. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmacogenetic testing market also includes sales of gene panels, deoxyribonucleic acid (DNA) sequencers, and home testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Pharmacogenetic Testing Market Characteristics
3. Pharmacogenetic Testing Market Supply Chain Analysis
4. Global Pharmacogenetic Testing Market Trends and Strategies
5. Pharmacogenetic Testing Market Analysis of End Use Industries
7. Global Pharmacogenetic Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Pharmacogenetic Testing Total Addressable Market (TAM) Analysis for the Market
9. Pharmacogenetic Testing Market Segmentation
10. Pharmacogenetic Testing Market Regional and Country Analysis
11. Asia-Pacific Pharmacogenetic Testing Market
12. China Pharmacogenetic Testing Market
13. India Pharmacogenetic Testing Market
14. Japan Pharmacogenetic Testing Market
15. Australia Pharmacogenetic Testing Market
16. Indonesia Pharmacogenetic Testing Market
17. South Korea Pharmacogenetic Testing Market
18. Taiwan Pharmacogenetic Testing Market
19. South East Asia Pharmacogenetic Testing Market
20. Western Europe Pharmacogenetic Testing Market
21. UK Pharmacogenetic Testing Market
22. Germany Pharmacogenetic Testing Market
23. France Pharmacogenetic Testing Market
24. Italy Pharmacogenetic Testing Market
25. Spain Pharmacogenetic Testing Market
26. Eastern Europe Pharmacogenetic Testing Market
27. Russia Pharmacogenetic Testing Market
28. North America Pharmacogenetic Testing Market
29. USA Pharmacogenetic Testing Market
30. Canada Pharmacogenetic Testing Market
31. South America Pharmacogenetic Testing Market
32. Brazil Pharmacogenetic Testing Market
33. Middle East Pharmacogenetic Testing Market
34. Africa Pharmacogenetic Testing Market
36. Pharmacogenetic Testing Market Competitive Landscape and Company Profiles
37. Pharmacogenetic Testing Market Other Major and Innovative Companies
40. Pharmacogenetic Testing Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Pharmacogenetic Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses pharmacogenetic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for pharmacogenetic testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharmacogenetic testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Whole Genome Sequencing; Whole Exome Sequencing; Array-Based Tests; Single Gene Tests2) By Drug Type: Prescription Drugs; Nutraceuticals; Recreational Drugs; Herbal Supplements; Vitamins; Over-The-Counter Medications
3) By Therapeutic Area: Cardiology; Gastroenterology; Anesthesiology; Genomics; Endocrinology; Immunology And Hypersensitivity; Dermatology; Gynecology; Oncology; Other Therapeutic Areas
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacies; Mail-Order Pharmacies; Direct-to-Customer Services
5) By End User: Healthcare Providers; Pharmaceutical And Biotechnology Companies; Centers And Academic Institutes; Other End Users
Subsegments:
1) By Whole Genome Sequencing: Illumina Sequencing; Ion Torrent Sequencing; Pacific Biosciences Sequencing; Oxford Nanopore Sequencing2) By Whole Exome Sequencing: Capture-Based Exome Sequencing; Targeted Enrichment Exome Sequencing; Hybridization-Based Exome Sequencing
3) By Array-Based Tests: SNP Array Testing; Expression Array Testing; Copy Number Variation Array Testing
4) By Single Gene Tests: Targeted Gene Panels; Mutation Detection Tests; Sequencing Of Specific Genes
Companies Mentioned: CVS Health Corporation; Thermo Fisher Scientific Inc.; Quest Diagnostics Incorporated; Eurofins Scientific Inc.; Bio-Rad Laboratories; Precision Medicine Advsiors; Azenta Life Sciences; Fulgent Genetics; Pacific Biosciences of California Inc.; Castle Biosciences; 23andMe Holding Co.; Helix Inc.; Genomind Inc.; MD Labs; Sonic Genetics; AutoGenomics Inc.; LabClinics SA; Gene By Gene Ltd.; Xcode Life Sciences; YouScript; RxGenomix LLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Pharmacogenetic Testing market report include:- CVS Health Corporation
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Eurofins Scientific Inc.
- Bio-Rad Laboratories
- Precision Medicine Advsiors
- Azenta Life Sciences
- Fulgent Genetics
- Pacific Biosciences of California Inc.
- Castle Biosciences
- 23andMe Holding Co.
- Helix Inc.
- Genomind Inc.
- MD Labs
- Sonic Genetics
- AutoGenomics Inc.
- LabClinics SA
- Gene By Gene Ltd.
- Xcode Life Sciences
- YouScript
- RxGenomix LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 16.58 Billion |
| Forecasted Market Value ( USD | $ 29.55 Billion |
| Compound Annual Growth Rate | 15.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
